The Challenge of Anticoagulation: Getting Research Into Practice

The GARFIELD-AF Registry: How Do These Data Inform Clinical Practice?

Activity Details
  • Credit Amounts:
    • CME: 0.50
    • Other: 0.50
  • Cost: Free
  • Release: May 3, 2017
  • Expires: May 2, 2020
  • Estimated Time to Complete:
    30 Minutes
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

A John Camm A John Camm, MD
Professor, Clinical Cardiology
St. George’s University of London
Consultant Cardiologist
St. George’s Hospital
London, United Kingdom

Needs Statement

International studies such as Global Anticoagulant Registry in the FIELD of atrial fibrillation (GARFIELD-AF) have been important in describing everyday antithrombotic treatment patterns in patients newly diagnosed with non-valvular AF and one or more additional investigator-defined risk factor for stroke. These data have provided valuable insights into the characteristics, risk profiles, management, and clinical outcomes of both treated and untreated patients newly diagnosed with non-valvular AF, as well as the evolving role of NOACs in this setting.

Target Audience

Health care professionals who are faced with challenges of anticoagulation treatment including the management of patients with VTE and/or patients with atrial fibrillation. These include practicing cardiologists, hematologists/oncologists, and geriatricians as well as specialists in Emergency Medicine, Internal Medicine, and all other subspecialist clinicians interested in anticoagulant therapy.

Objectives

Upon completion of this educational activity, participants will be able to:

  • Describe the risk factors for stroke and bleeding complications in patients with atrial fibrillation
  • Select appropriate anticoagulant for the prevention of thromboembolic stroke in patients with atrial fibrillation

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and Thrombosis Research Institute. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement

Other
UK Healthcare CECentral certifies this activity for 0.50 hours of participation.

Faculty Disclosure

A. John Camm, MD, (Speaker) has relevant financial relationships with commercial interests as follows:
Bayer, BMS/Pfizer, Daiichi Sankyo, Boehringher Ingelheim - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria

Christopher B. Granger, MD, (Planner) has relevant financial relationships with commercial interests as follows:
Armetheon - Principal Investigator, Research Support, Salary Support
AstraZeneca - Principal Investigator, Consultant & Other Services, Research Support, Consulting Fee
Bayer - Principal Investigator, Consultant & Other Services, Salary Support, Consulting Fee
Boehringer Ingelheim - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Bristol Myers Squibb - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Eli Lilly - Consultant & Other Services, Consulting Fee
Daiichi Sankyo - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
FDA - Principal Investigator, Research Support
Gilead - Consultant & Other Services, Consulting Fee
Glaxo SmithKline - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Hoffman-La Roche - Consultant & Other Services, Consulting Fee
Janssen Pharmaceuticals - Principal Investigator, Research Support
The Medicines Company - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Medtronic Foundation - Principal Investigator, Research Support, Salary Support

Lord Ajay Kakkar, BSc, MBBS, PhD, FRCS, (Planner) has relevant financial relationships with commercial interests as follows:
Aspen Pharma - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria
Bayer Healthcare - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria
Boehringer Ingelheim Pharma - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria
Daiichi Sankyo Europe - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria
Sanofi SA - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria

No other planners or reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Thrombosis Research Institute.

Supported by an unrestricted educational grant from Bayer.

FRONTLINE 2 Survey

The Fundamental Research in Oncology and Thrombosis (FRONTLINE 2) Survey is designed to evaluate how clinicians perceive the risk of venous thromboembolism in cancer patients and to provide insight into current strategies for thromboprophylaxis and management. It has been developed with the guidance of an international advisory board of experts in this field. This survey is coordinated by the Thrombosis Research Institute, London. It has been developed with the guidance of an international advisory board of experts in this field. All replies will be treated in the strictest confidence. The survey is split into 5 Sections (A-E) and will take approximately 20 - 30 minutes to complete.

To complete the survey, visit http://frontline2.tri-london.ac.uk/